341 related articles for article (PubMed ID: 33569681)
1. A Review of Complement Activation in SLE.
Weinstein A; Alexander RV; Zack DJ
Curr Rheumatol Rep; 2021 Feb; 23(3):16. PubMed ID: 33569681
[TBL] [Abstract][Full Text] [Related]
2. Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome.
Lonati PA; Scavone M; Gerosa M; Borghi MO; Pregnolato F; Curreli D; Podda G; Femia EA; Barcellini W; Cattaneo M; Tedesco F; Meroni PL
Front Immunol; 2019; 10():773. PubMed ID: 31031764
[TBL] [Abstract][Full Text] [Related]
3. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.
Hui-Yuen JS; Gartshteyn Y; Ma M; O'Malley T; Conklin J; Eichenfield AH; Imundo LF; Dervieux T; Askanase AD
Lupus; 2018 Dec; 27(14):2262-2268. PubMed ID: 30376789
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
5. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
[TBL] [Abstract][Full Text] [Related]
6. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
Kao AH; Navratil JS; Ruffing MJ; Liu CC; Hawkins D; McKinnon KM; Danchenko N; Ahearn JM; Manzi S
Arthritis Rheum; 2010 Mar; 62(3):837-44. PubMed ID: 20187154
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM
Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444
[TBL] [Abstract][Full Text] [Related]
8. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
Front Immunol; 2019; 10():885. PubMed ID: 31134052
[TBL] [Abstract][Full Text] [Related]
9. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
Ramsey-Goldman R; Alexander RV; Massarotti EM; Wallace DJ; Narain S; Arriens C; Collins CE; Saxena A; Putterman C; Kalunian KC; O'Malley T; Dervieux T; Weinstein A
Arthritis Rheumatol; 2020 Jan; 72(1):78-88. PubMed ID: 31469249
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus.
Negoro N; Okamura M; Takeda T; Koda S; Amatsu K; Inoue T; Curd JG; Kanayama Y
Arthritis Rheum; 1989 Oct; 32(10):1233-42. PubMed ID: 2803326
[TBL] [Abstract][Full Text] [Related]
11. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
12. Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.
Dervieux T; Conklin J; Ligayon JA; Wolover L; O'Malley T; Alexander RV; Weinstein A; Ibarra CA
J Immunol Methods; 2017 Jul; 446():54-59. PubMed ID: 28389175
[TBL] [Abstract][Full Text] [Related]
13. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.
Mejia-Vilet JM; Gómez-Ruiz IA; Cruz C; Méndez-Pérez RA; Comunidad-Bonilla RA; Uribe-Uribe NO; Nuñez-Alvarez CA; Morales-Buenrostro LE
Clin Rheumatol; 2021 Jun; 40(6):2233-2242. PubMed ID: 33170371
[TBL] [Abstract][Full Text] [Related]
14. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.
Putterman C; Furie R; Ramsey-Goldman R; Askanase A; Buyon J; Kalunian K; Chatham WW; Massarotti E; Kirou K; Jordan N; Blanco I; Weinstein A; Chitkara P; Manzi S; Ahearn J; O'Malley T; Conklin J; Ibarra C; Barken D; Dervieux T
Lupus Sci Med; 2014; 1(1):e000056. PubMed ID: 25396070
[TBL] [Abstract][Full Text] [Related]
15. Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus.
Gartshteyn Y; Mor A; Shimbo D; Khalili L; Kapoor T; Geraldino-Pardilla L; Alexander RV; Conklin J; Dervieux T; Askanase AD
Clin Immunol; 2021 Jul; 228():108755. PubMed ID: 33984497
[TBL] [Abstract][Full Text] [Related]
16. Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis.
Qin S; Wang X; Wang J; Wu H
Lupus; 2024 Feb; 33(2):111-120. PubMed ID: 38227433
[No Abstract] [Full Text] [Related]
17. Cell-bound complement activation products associate with lupus severity in SLE.
Arriens C; Alexander RV; Narain S; Saxena A; Collins CE; Wallace DJ; Massarotti E; Conklin J; Kalunian KC; Putterman C; Ramsey-Goldman R; Buyon JP; Askanase A; Furie RA; James JA; Bello GA; Manzi S; Ahearn J; O'Malley T; Weinstein A; Dervieux T
Lupus Sci Med; 2020 Apr; 7(1):. PubMed ID: 32371480
[TBL] [Abstract][Full Text] [Related]
18. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.
Svenungsson E; Gustafsson JT; Grosso G; Rossides M; Gunnarsson I; Jensen-Urstad K; Larsson A; Ekdahl KN; Nilsson B; Bengtsson AA; Lood C
Rheumatology (Oxford); 2020 Nov; 59(11):3264-3274. PubMed ID: 32259250
[TBL] [Abstract][Full Text] [Related]
19. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.
Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB
Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
Li J; An L; Zhang Z
Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
